Pattern of recurrence in patients with endometrial cancer: A retrospective study

Eur J Surg Oncol. 2020 Sep;46(9):1697-1702. doi: 10.1016/j.ejso.2020.03.203. Epub 2020 Mar 13.

Abstract

Introduction: Endometrial cancer (EC) known prognostic factors are not sufficient to predict either outcome or recurrence rate/site: to investigate EC recurrence patterns according to ESMO-ESGO-ESTRO risk classes, could be beneficial for a more tailored adjuvant treatment and follow-up schedule.

Methods: 758 women diagnosed with EC, and a 5-years follow-up, were enrolled: they were divided into the ESMO-ESGO-ESTRO risk classes (low LR, intermediate IR, intermediate-high I-HR, and highrisk HR) and surgically treated as recommended, followed by adjuvants therapies when appropriate.

Results: Higher recurrence rate (RR) was significantly detected (p < 0,001) in the HR group (40,3%) compared to LR (9,6%), IR (16,7%) and I-HR (17,1%). Recurrences were detected more frequently at distant sites (64%) compared to pelvic (25,3%) and lymph nodes (10,7%) recurrences (p < 0,0001): only in LR group, no differences were detected between local and distant recurrences. 5-Year distant-free (LR 99%, IR 94%,I-HR 86%, HR 88%) and local-free survivals (LR 99%, IR 100%,I-HR 98%, HR 95%) significantly differ between groups (p < 0,0001 and p = 0,003, respectively). Adjuvant therapy modifies RRs only in LR group (p = 0,01).

Conclusion: To identify biological factors to stratify patients at higher risk of relapse is needed. Distant site relapse could be the main reason of endometrial cancer failure follow-up, independently or in addition to their risk class prognosis.

Keywords: ESMO-ESGO-ESTRO risk Classes; Endometrial cancer; Pattern of recurrence.

Publication types

  • Observational Study

MeSH terms

  • Adenocarcinoma, Clear Cell / pathology
  • Adenocarcinoma, Clear Cell / therapy
  • Adult
  • Aged
  • Aged, 80 and over
  • Anthracyclines / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brachytherapy
  • Carcinoma, Adenosquamous / pathology
  • Carcinoma, Adenosquamous / therapy
  • Carcinoma, Endometrioid / pathology
  • Carcinoma, Endometrioid / therapy*
  • Chemoradiotherapy, Adjuvant
  • Disease-Free Survival
  • Endometrial Neoplasms / pathology
  • Endometrial Neoplasms / therapy*
  • Female
  • Humans
  • Hysterectomy
  • Laparoscopy
  • Lymph Node Excision
  • Lymph Nodes / pathology*
  • Lymphatic Metastasis
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Metastasis*
  • Neoplasm Recurrence, Local / epidemiology*
  • Neoplasms, Cystic, Mucinous, and Serous / pathology
  • Neoplasms, Cystic, Mucinous, and Serous / therapy
  • Omentum
  • Peritoneal Lavage
  • Platinum Compounds / administration & dosage
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Risk Assessment
  • Robotic Surgical Procedures
  • Salpingo-oophorectomy
  • Taxoids / administration & dosage

Substances

  • Anthracyclines
  • Platinum Compounds
  • Taxoids